76 related articles for article (PubMed ID: 17473661)
1. Phase I study of lenalidomide in solid tumors.
Miller AA; Case D; Harmon M; Savage P; Lesser G; Hurd D; Melin SA
J Thorac Oncol; 2007 May; 2(5):445-9. PubMed ID: 17473661
[TBL] [Abstract][Full Text] [Related]
2. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.
Sharma RA; Steward WP; Daines CA; Knight RD; O'Byrne KJ; Dalgleish AG
Eur J Cancer; 2006 Sep; 42(14):2318-25. PubMed ID: 16899362
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of pomalidomide given for patients with advanced solid tumors.
Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
[TBL] [Abstract][Full Text] [Related]
4. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
Drappatz J; Wong ET; Schiff D; Kesari S; Batchelor TT; Doherty L; Lafrankie DC; Ramakrishna N; Weiss S; Smith ST; Ciampa A; Zimmerman J; Ostrowsky L; David K; Norden A; Barron L; Sceppa C; Black PM; Wen PY
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):222-7. PubMed ID: 18513880
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide therapy for metastatic renal cell carcinoma.
Amato RJ; Hernandez-McClain J; Saxena S; Khan M
Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Bilen MA; Fu S; Falchook GS; Ng CS; Wheler JJ; Abdelrahim M; Erguvan-Dogan B; Hong DS; Tsimberidou AM; Kurzrock R; Naing A
Cancer Chemother Pharmacol; 2015 Apr; 75(4):869-74. PubMed ID: 25666183
[TBL] [Abstract][Full Text] [Related]
7. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE
J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
Zhang MM; Chan JK; Husain A; Guo HY; Teng NN
Gynecol Oncol; 2007 Apr; 105(1):194-8. PubMed ID: 17257661
[TBL] [Abstract][Full Text] [Related]
11. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Dueck G; Chua N; Prasad A; Finch D; Stewart D; White D; van der Jagt R; Johnston J; Belch A; Reiman T
Cancer; 2010 Oct; 116(19):4541-8. PubMed ID: 20572046
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
14. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Hitz F; Fischer N; Pabst T; Caspar C; Berthod G; Eckhardt K; Berardi Vilei S; Zucca E; Mey U;
Ann Hematol; 2013 Aug; 92(8):1033-40. PubMed ID: 23592273
[TBL] [Abstract][Full Text] [Related]
16. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Dahut WL; Aragon-Ching JB; Woo S; Tohnya TM; Gulley JL; Arlen PM; Wright JJ; Ventiz J; Figg WD
J Clin Pharmacol; 2009 Jun; 49(6):650-60. PubMed ID: 19451403
[TBL] [Abstract][Full Text] [Related]
20. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]